⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 15, 2025

Figure S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR⁺/HER2⁻ Breast Cancer

Xiu-Zhi Zhu Hu-Yun-Long Zhang Yi-Fan Zhou Yi-Yu Chen Tong Fu Ming-Liang Jin Ya-Xin Zhao Yi-Fan Xie Xiaohua Zeng Xi Jin Yi‐Zhou Jiang Zhi‐Ming Shao

View at Publisher

Ask AI

Bookmark

Share

Key Points

Subtyping-directed precision treatment improves therapy effectiveness for HR+/HER2− breast cancer.
Drug susceptibility mechanisms of SNF3 identified using PDO reveal critical therapeutic insights.
Omics features analyzed through precision treatment strategies in breast cancer open new avenues for individualized care.
Enhanced outcomes may result from tailored therapies, highlighting the need for ongoing research in drug mechanisms.

Implication

Subtyping-directed intervention reveals drug susceptibility mechanisms in HR+/HER2− breast cancer cases, indicating improved outcomes.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/68f199bfde32064e504dcb93 https://doi.org/10.1158/0008-5472.30363472

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
2Figure S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
3Figure S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
4Figure S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
5Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025

Figure S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
Table S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025
Table S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer2025